> Details

Einarsdottir, Berglind O.; Karlsson, Joakim; Söderberg, Elin M. V.; Lindberg, Mattias F.; Funck-Brentano, Elisa; Jespersen, Henrik; Brynjolfsson, Siggeir F.; Olofsson Bagge, Roger; Carstam, Louise; Scobie, Martin; Koolmeister, Tobias; Wallner, Olof; Stierner, Ulrika; Berglund, Ulrika Warpman; Ny, Lars; Nilsson, Lisa M.; Larsson, Erik; Helleday, Thomas; Nilsson, Jonas A.

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
  • Contributor: Einarsdottir, Berglind O.; Karlsson, Joakim; Söderberg, Elin M. V.; Lindberg, Mattias F.; Funck-Brentano, Elisa; Jespersen, Henrik; Brynjolfsson, Siggeir F.; Olofsson Bagge, Roger; Carstam, Louise; Scobie, Martin; Koolmeister, Tobias; Wallner, Olof; Stierner, Ulrika; Berglund, Ulrika Warpman; Ny, Lars; Nilsson, Lisa M.; Larsson, Erik; Helleday, Thomas; Nilsson, Jonas A.
  • imprint: Springer Science and Business Media LLC, 2018
  • Published in: Cell Death & Disease
  • Language: English
  • DOI: 10.1038/s41419-018-0865-6
  • ISSN: 2041-4889
  • Keywords: Cancer Research ; Cell Biology ; Cellular and Molecular Neuroscience ; Immunology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Karonudib (TH1579) is a novel compound that exerts anti-tumor activities and has recently entered phase I clinical testing. The aim of this study was to conduct a pre-clinical trial in patient-derived xenografts to identify the possible biomarkers of response or resistance that could guide inclusion of patients suffering from metastatic melanoma in phase II clinical trials. Patient-derived xenografts from 31 melanoma patients with metastatic disease were treated with karonudib or a vehicle for 18 days. Treatment responses were followed by measuring tumor sizes, and the models were categorized in the response groups. Tumors were harvested and processed for RNA sequencing and protein analysis. To investigate the effect of karonudib on T-cell-mediated anti-tumor activities, tumor-infiltrating T cells were injected in mice carrying autologous tumors and the mice treated with karonudib. We show that karonudib has heterogeneous anti-tumor effect on metastatic melanoma. Thus, based on the treatment responses, we could divide the 31 patient-derived xenografts in three treatment groups: progression group (32%), suppression group (42%), and regression group (26%). Furthermore, we show that karonudib has anti-tumor effect, irrespective of major melanoma driver mutations. Also, we identify high expression of <jats:italic>ABCB1</jats:italic>, which codes for p-gp pumps as a resistance biomarker. Finally, we show that karonudib treatment does not hamper T-cell-mediated anti-tumor responses. These findings can be used to guide future use of karonudib in clinical use with a potential approach as precision medicine.</jats:p>
  • Access State: Open Access